OrbiMed’s NASH Terns

Why OrbiMed led $80 million B round for U.S.-China NASH company Terns

Terns Pharmaceuticals Inc. brings a dual U.S.-China strategy and a diverse pipeline to OrbiMed’s non-alcoholic steatohepatitis investment portfolio.

OrbiMed co-led the biotech’s $80 million series B on Oct. 30 with fellow new investor Vivo Capital. Decheng Capital, also a

Read the full 386 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE